Search - tctmd.com

Displaying 21 - 40 of 56

Presentation TCT 2018

Low Surgical Risk Aortic Stenosis In The Us: The Patient Really Wants TAVR

Presenter: Vinayak Bapat, Susheel K. Kodali, Philippe Genereux, Martin B. Leon, Scott Lim, Michael J. Mack, Raj Makkar, Patrick T. O'Gara, Michael J. Reardon, Allan Schwartz

September 23, 2018

Presentation TCT 2018

Program Update: The LOTUS TAVR System

Presenter: Michael J. Reardon

September 22, 2018

Presentation TCT 2018

My Crystal Ball - Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis Once the Cycle of Low-Risk Studies is Completed

Presenter: Allan Schwartz, Stephan Windecker, Michael J. Reardon

September 22, 2018

Presentation TCT 2018

TCT-15: Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanically- versus Self-Expandable Valves: Results From The REPRISE III Randomized Trial

Presenter: Charles J. Davidson, Jeffrey J. Popma, Michael J. Reardon

September 21, 2018

News Conference News TCT 2017

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Yael L. Maxwell

November 09, 2017

Presentation TCT 2017

Point A Multi-Device Lesion-Specific Approach is Preferred!

Presenter: Michael J. Reardon

November 01, 2017

Presentation TCT 2017

The Compelling Saga of Stroke after TAVR: Key Messages From NeuroARC

Presenter: Michael J. Reardon, Didier Tchetche, Alexandra J. Lansky

October 31, 2017

Presentation TCT 2017

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Presenter: Michael J. Reardon

October 31, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

Presentation TCT 2016

TCT 36: Frailty in Intermediate Risk Patients Undergoing Transcatheter or Surgical Aortic Valve Replacement, Cut Points and Relationship With Outcomes: An Analysis of the Placement of Aortic Transcatheter Valves (PARTNER) 2 Cohort A Randomized Trial

Presenter: Charles J. Davidson, Michael J. Reardon, Philip Green

October 31, 2016

Presentation TCT 2016

TCT 35: Predictors of Early Aortic Valve Rehospitalization Following Self-Expanding Transcatheter Aortic Valve Replacement: Results From the CoreValve US Trial Program

Presenter: Charles J. Davidson, Michael J. Reardon, James B. Hermiller Jr.

October 31, 2016

Title Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

Presentation TCT 2016

TCT 34: Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

Presenter: Charles J. Davidson, Michael J. Reardon, Suzanne Baron

October 31, 2016

Presentation TCT 2016

TCT 33: Predictors of Hospital Readmissions After Transcatheter Aortic Valve Replacement

Presenter: Charles J. Davidson, Michael J. Reardon, James Harvey

October 31, 2016

Presentation TCT 2015

TCT 106: Cardiovascular Magnetic Resonance for the Evaluation of Aortic Regurgitation Following Transcatheter Aortic Valve Replacement Insights on Clinical Outcomes

Presenter: Michael J. Reardon, Torsten P. Vahl, Henrique Ribeiro

October 13, 2015

Presentation TCT 2015

TCT 105: Transcatheter Aortic Valve Implantation Using a New Second-Generation TAVI System J-Valve for High-Risk Patients With Pure Aortic Regurgitation

Presenter: Michael J. Reardon, Torsten P. Vahl, Yingqiang Guo

October 13, 2015

Presentation TCT 2015

TCT 104: Clinical Outcomes of Transcatheter Aortic Valve Replacement for Bicuspid Aortic Valve Stenosis

Presenter: Michael J. Reardon, Torsten P. Vahl, Sung-Han Yoon

October 13, 2015

Presentation TCT 2015

TCT 103: National Variation in Post-TAVR Antithrombotic Therapy Utilization and Associated Outcomes Insights From the STS/ACC TVT Registry

Presenter: Michael J. Reardon, Torsten P. Vahl, Matthew Sherwood

October 13, 2015

Presentation TCT 2015

TCT 102: SAPIEN 3 Implantation in Failed Surgical Aortic Bioprostheses Matched Comparison and Insights From the Valve-in-Valve International Data (VIVID) Registry

Presenter: Michael J. Reardon, Torsten P. Vahl, Moritz Seiffert

October 13, 2015

Presentation TCT 2015

TCT 101: Experience With Cerebral Protection During Transcatheter Aortic Valve Replacement The ALSTER Registry

Presenter: Michael J. Reardon, Torsten P. Vahl, Tobias Schmidt

October 13, 2015

Presentation TCT 2015

TCT 100: Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease One-Year Outcomes From the CoreValve US Expanded Use Study

Presenter: Michael J. Reardon, Torsten P. Vahl, Daniel O'Hair

October 13, 2015

Advertisement

Low Surgical Risk Aortic Stenosis In The Us: The Patient Really Wants TAVR

Program Update: The LOTUS TAVR System

My Crystal Ball - Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis Once the Cycle of Low-Risk Studies is Completed

TCT-15: Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanically- versus Self-Expandable Valves: Results From The REPRISE III Randomized Trial

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Point A Multi-Device Lesion-Specific Approach is Preferred!

The Compelling Saga of Stroke after TAVR: Key Messages From NeuroARC

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

TCT 36: Frailty in Intermediate Risk Patients Undergoing Transcatheter or Surgical Aortic Valve Replacement, Cut Points and Relationship With Outcomes: An Analysis of the Placement of Aortic Transcatheter Valves (PARTNER) 2 Cohort A Randomized Trial

TCT 35: Predictors of Early Aortic Valve Rehospitalization Following Self-Expanding Transcatheter Aortic Valve Replacement: Results From the CoreValve US Trial Program

TCT 34: Effect of Sapien-3 Transcatheter Valve Implant on Health Status in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk: Results from the PARTNER S3i Trial

TCT 33: Predictors of Hospital Readmissions After Transcatheter Aortic Valve Replacement

TCT 106: Cardiovascular Magnetic Resonance for the Evaluation of Aortic Regurgitation Following Transcatheter Aortic Valve Replacement Insights on Clinical Outcomes

TCT 105: Transcatheter Aortic Valve Implantation Using a New Second-Generation TAVI System J-Valve for High-Risk Patients With Pure Aortic Regurgitation

TCT 104: Clinical Outcomes of Transcatheter Aortic Valve Replacement for Bicuspid Aortic Valve Stenosis

TCT 103: National Variation in Post-TAVR Antithrombotic Therapy Utilization and Associated Outcomes Insights From the STS/ACC TVT Registry

TCT 102: SAPIEN 3 Implantation in Failed Surgical Aortic Bioprostheses Matched Comparison and Insights From the Valve-in-Valve International Data (VIVID) Registry

TCT 101: Experience With Cerebral Protection During Transcatheter Aortic Valve Replacement The ALSTER Registry

TCT 100: Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease One-Year Outcomes From the CoreValve US Expanded Use Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content